- cafead Jun 18, 2024 at 11:42: AM
via The world’s best-selling medicine is still adding new uses, and its latest FDA approval marks a first in the cancer immunotherapy class.
Merck & Co.’s Keytruda has received the FDA’s green light for use in combination with chemotherapy, followed by the PD-1 inhibitor as a single agent, in patients with primary advanced or recurrent endometrial cancer, the company said Monday.
article source
Merck & Co.’s Keytruda has received the FDA’s green light for use in combination with chemotherapy, followed by the PD-1 inhibitor as a single agent, in patients with primary advanced or recurrent endometrial cancer, the company said Monday.
article source